## Edgar Filing: SPECTOR STEVEN W - Form 4

SPECTOR S	TEVEN W											
Form 4 March 06, 20	10											
									OMB AF	PPROVAL		
FORM	<b>4</b> UNITED	) STATES	S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							3235-0287		
Check th if no long subject to Section 1 Form 4 o Form 5	ger <b>STATE</b> 6. r	box <b>STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF</b> <b>SECURITIES</b>										
obligation may cont <i>See</i> Instru 1(b).	inue. Section 17	section 17(a) of the Fubic Official Company Act of 1955 of Section										
(Print or Type I	Responses)											
1. Name and Address of Reporting Person <u></u> SPECTOR STEVEN W			2. Issuer Name <b>and</b> Ticker or Trading Symbol ARENA PHARMACEUTICALS					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) 3.				RNA] Earliest Tra ay/Year) )18	ansaction			Director 10% Owner X Officer (give title Other (specify below) below) EVP, General Counsel & Sec				
PHARMAC	EUTICALS, IN DGE DRIVE	NC., 6154	00/02/20	,10				EvP, Ger	ierai Counsei &	z sec		
SAN DIEG	(Street) 4. If Ame Filed(Mon				te Original			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative S	ecuri	ties Acq	uired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Dee (Month/Day/Year) Execution any (Month/		med	3.	(Instr. 3, 4 and 5)			Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
G				Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				
Common Stock	03/02/2018			А	11,205 (1)	А	\$0	23,564	D			
Common Stock	03/02/2018			F	3,874 (2)	D	\$ 42.8	19,690	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: SPECTOR STEVEN W - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
SPECTOR STEVEN W C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO, CA 92121			EVP, General Counsel & Sec				
Signatures							
/s/ Steven W							

/s/ Steven W. 03/06/2018 Spector

<u>\*\*</u>Signature of Reporting Person Date

e of erson

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On March 11, 2015, the Reporting Person was granted performance restricted stock units. On March 2, 2018, it was determined that 11,205 of the shares subject to the grant vested.
- (2) The amount represents shares withheld for payment of tax liability relating to vesting of performance restricted stock units.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.